JPH08507916A - Ｍ−ｃｓｆの結晶化 - Google Patents

Ｍ−ｃｓｆの結晶化

Info

Publication number
JPH08507916A
JPH08507916A JP6501713A JP50171394A JPH08507916A JP H08507916 A JPH08507916 A JP H08507916A JP 6501713 A JP6501713 A JP 6501713A JP 50171394 A JP50171394 A JP 50171394A JP H08507916 A JPH08507916 A JP H08507916A
Authority
JP
Japan
Prior art keywords
csf
dimer
csfα
polypeptide
crystallized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP6501713A
Other languages
English (en)
Japanese (ja)
Inventor
パンディット，ジェイバードハン
ジャンカリク，ジャーミラ
キム，スン−ホウ
コス，クリストン
ハレンベック，ロバート
リサ フィアー，アンナ
テイラー，エリック
ヤマモト，ラルフ
ボーム，アンドリュー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of JPH08507916A publication Critical patent/JPH08507916A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7153—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for colony-stimulating factors [CSF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP6501713A 1992-06-09 1993-06-09 Ｍ−ｃｓｆの結晶化 Withdrawn JPH08507916A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89651292A 1992-06-09 1992-06-09
US07/896,512 1992-06-09
PCT/US1993/005548 WO1993025687A1 (en) 1992-06-09 1993-06-09 Crystallization of m-csf

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2004155357A Division JP2004285076A (ja) 1992-06-09 2004-05-25 Ｍ−ｃｓｆの結晶化

Publications (1)

Publication Number Publication Date
JPH08507916A true JPH08507916A (ja) 1996-08-27

Family

ID=25406334

Family Applications (2)

Application Number Title Priority Date Filing Date
JP6501713A Withdrawn JPH08507916A (ja) 1992-06-09 1993-06-09 Ｍ−ｃｓｆの結晶化
JP2004155357A Withdrawn JP2004285076A (ja) 1992-06-09 2004-05-25 Ｍ−ｃｓｆの結晶化

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2004155357A Withdrawn JP2004285076A (ja) 1992-06-09 2004-05-25 Ｍ−ｃｓｆの結晶化

Country Status (7)

Country Link
US (2) US5866114A (OSRAM)
EP (2) EP0668914B1 (OSRAM)
JP (2) JPH08507916A (OSRAM)
AT (1) ATE195553T1 (OSRAM)
CA (1) CA2137793C (OSRAM)
DE (1) DE69329247T2 (OSRAM)
WO (1) WO1993025687A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013513367A (ja) * 2009-12-10 2013-04-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 優先的にヒトｃｓｆ１ｒ細胞外ドメイン４に結合する抗体及びそれらの使用

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
WO1997033613A1 (en) * 1996-03-14 1997-09-18 Board Of Trustees Of The University Of Illinois Parasite-derived anti-inflammatory immunomodulatory protein
WO2001034177A2 (en) * 1999-11-08 2001-05-17 The Government Of The United States Of America, A S Represented By The Secretary, Department Of Hea Lth & Human Services, The National Institutes Of Health Method of treating a viral infection using antagonists of macrophage colony stimulating factor
DK1772464T3 (da) 2001-02-09 2009-12-14 Genentech Inc Fremgangsmåder til identificering af indirekte agonister af IGF-1
US7247618B2 (en) * 2001-04-30 2007-07-24 Tripathi Rajavashisth Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
BR0211071A (pt) 2001-07-11 2004-12-21 Maxygen Holdings Ltd Conjugado polipeptìdico apresentando atividade de g-csf, método para preparar um conjugado de g-csf, composição, método para tratar um mamìfero sofrendo de um nìvel neutrofìlico insuficiente, e, uso do conjugado polipeptìdico
US7563595B2 (en) * 2002-11-08 2009-07-21 University Of South Florida Nucleic acids encoding functional splice variants of the α7 nicotinic acetylcholine receptor subunit and methods for producing the encoded proteins
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
WO2005057169A2 (en) * 2003-12-05 2005-06-23 Trellis Bioscience, Inc. Homogeneous competition assays
EP1706137A2 (en) * 2004-01-21 2006-10-04 Chiron Corporation M-csf muteins and uses thereof
US20060094081A1 (en) * 2004-10-22 2006-05-04 Carsten Schubert Crystal structure of the c-fms kinase domain: applications and use of heterologous substitutions of kinase insert domains for crystallization
JP5137821B2 (ja) 2005-06-01 2013-02-06 マキシジェン， インコーポレイテッド Ｐｅｇ化されたｇ−ｃｓｆポリペプチドおよびその製造方法
KR100970770B1 (ko) 2008-02-12 2010-07-16 한국기초과학지원연구원 결정성 재조합 단백질 휴먼 에스피오티 및 이의 결정화방법
US8183207B2 (en) * 2008-11-26 2012-05-22 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules
WO2010062399A2 (en) * 2008-11-26 2010-06-03 Five Prime Therapeutics, Inc. Csf1r extracellular domain fusion molecules and treatments using same
AR075899A1 (es) * 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
US9169323B2 (en) 2010-03-05 2015-10-27 Hoffmann-La Roche Inc. Antibodies against human CSF-1R
EP2542588A1 (en) 2010-03-05 2013-01-09 F. Hoffmann-La Roche AG Antibodies against human csf-1r and uses thereof
NZ603193A (en) 2010-05-04 2014-07-25 Five Prime Therapeutics Inc Antibodies that bind csf1r
US20140378537A1 (en) 2011-09-09 2014-12-25 Genentech, Inc. Treatment of th17 mediated inflammatory diseases
BR112014012624A2 (pt) 2011-12-15 2018-10-09 F Hoffmann-La Roche Ag anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
HK1212214A1 (en) 2012-08-31 2016-06-10 戊瑞治疗有限公司 Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
BR112016029460A2 (pt) 2014-06-23 2017-10-24 Five Prime Therapeutics Inc métodos para tratar artrite reumatoide
EA036261B1 (ru) 2014-10-29 2020-10-20 Файв Прайм Терапьютикс, Инк. Комбинированное лечение злокачественного новообразования
EP3237447B1 (en) 2014-12-22 2020-12-02 Five Prime Therapeutics, Inc. Anti-csf1r antibodies for treating pvns
PT3283527T (pt) 2015-04-13 2021-03-03 Five Prime Therapeutics Inc Terapêutica de combinação para o cancro
CN109790220A (zh) 2016-08-25 2019-05-21 豪夫迈·罗氏有限公司 与巨噬细胞激活剂组合的抗csf-1r抗体的间歇给药
EP3558360A1 (en) 2016-12-22 2019-10-30 F. Hoffmann-La Roche AG Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment
CN106843149A (zh) * 2017-03-28 2017-06-13 吴小江 一种机械零固件产品加工系统
JP2020535119A (ja) 2017-09-13 2020-12-03 ファイヴ プライム セラピューティクス インク 膵臓がんの抗ｃｓｆ１ｒおよび抗ｐｄ−１抗体組合せ併用療法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4672108A (en) * 1981-12-07 1987-06-09 Hoffmann-La Roche Inc. Crystalline human leukocyte interferon
US4582788A (en) 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
US4966911A (en) * 1984-11-20 1990-10-30 Washington Research Foundation Immunoregulatory agents
US4847201A (en) * 1985-02-05 1989-07-11 Cetus Corporation DNA encoding for CSF-1 and accompanying recombinant systems
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
JPS62106000A (ja) * 1985-10-30 1987-05-16 Fujitsu Ltd 生体高分子結晶自動作製装置
US4908773A (en) * 1987-04-06 1990-03-13 Genex Corporation Computer designed stabilized proteins and method for producing same
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4881175A (en) * 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5032676A (en) 1986-10-14 1991-07-16 Immunex Corporation Nonglycosylated analogs of human colony stimulating factors
WO1988003173A2 (en) * 1986-10-24 1988-05-05 Cetus Corporation New forms of colony stimulating factor-1
US4929700A (en) * 1987-04-16 1990-05-29 Cetus Corporation Production of purified, biologically active, bacterially produced recombinant human CSF-1
IL86090A (en) * 1987-04-16 1993-03-15 Cetus Oncology Corp Production of purified, biologically active, bacterially produced recombinant human csf-1
US4833233A (en) * 1987-08-20 1989-05-23 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Human serum albumin crystals and method of preparation
DE68918331T2 (de) * 1988-06-03 1995-05-18 Chugai Pharmaceutical Co Ltd Menschlicher kristallinischer Granulocyt-Koloniestimulierungsfaktor und dessen Herstellung.
US5109119A (en) * 1989-06-06 1992-04-28 Schering Corporation Crystalline r-h-gm-csf and method
IE66494B1 (en) * 1989-09-26 1996-01-10 Immunex Corp Granulocyte-colony stimulating factor receptors
EP0506866B1 (en) * 1989-12-21 1993-10-20 Novo Nordisk A/S Method for crystallization of enzymes
DE69231467T2 (de) * 1991-05-10 2001-01-25 Genentech, Inc. Auswählen von agonisten und antagonisten von liganden

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013513367A (ja) * 2009-12-10 2013-04-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 優先的にヒトｃｓｆ１ｒ細胞外ドメイン４に結合する抗体及びそれらの使用
JP2015120697A (ja) * 2009-12-10 2015-07-02 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 優先的にヒトｃｓｆ１ｒ細胞外ドメイン４に結合する抗体及びそれらの使用
JP2017123850A (ja) * 2009-12-10 2017-07-20 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 優先的にヒトｃｓｆ１ｒ細胞外ドメイン４に結合する抗体及びそれらの使用

Also Published As

Publication number Publication date
EP0668914A1 (en) 1995-08-30
WO1993025687A1 (en) 1993-12-23
DE69329247D1 (de) 2000-09-21
US6184354B1 (en) 2001-02-06
JP2004285076A (ja) 2004-10-14
EP0955365A2 (en) 1999-11-10
DE69329247T2 (de) 2001-05-31
US5866114A (en) 1999-02-02
EP0955365A3 (en) 2000-12-20
ATE195553T1 (de) 2000-09-15
EP0668914B1 (en) 2000-08-16
CA2137793A1 (en) 1993-12-23
CA2137793C (en) 2003-04-22

Similar Documents

Publication Publication Date Title
JPH08507916A (ja) Ｍ−ｃｓｆの結晶化
Robinson et al. The crystal structure and biological function of leukemia inhibitory factor: implications for receptor binding
US20020147306A1 (en) Peptides that modulate the interaction of B class ephrins and PDZ domains
JP2002500887A (ja) Ａｃｐｌｄｎａおよびポリペプチド
JP2019513224A (ja) 体重を調節するための組成物及び方法
IE903467A1 (en) Granulocyte-colony stimulating factor receptors
JP2001526892A (ja) Ｓｉｇｉｒｒｄｎａおよびポリペプチド
JP3602442B2 (ja) ＩＬ−１δのＤＮＡおよびポリペプチド
CN101883787B (zh) 一种可溶性tnf受体突变体
JP5081277B2 (ja) ＩＬ−１ゼータ、ＩＬ−１ゼータスプライス変異体およびＸｒｅｃ２のＤＮＡおよびポリペプチド
US6025146A (en) Identification of M-CSF agonists and antagonists
US20020034802A1 (en) Crystals of the alpha 1 beta 1 integrin I-domain and their use
JP4623342B2 (ja) Ｉｌ−１エータのｄｎａ及びポリペプチド
US20090263784A1 (en) Three-dimensional structure of prostaglandin d synthase and utilization thereof
EP0646129A4 (en) MOLECULES, WHICH ARE SIMILAR TO THE TYROSIN KINASE OF THE RECEPTOR TYPE (01/13/94).
WO2000037500A1 (en) Three dimensional structure of a sterile alpha motif domain
WO1996001319A1 (en) Variants of leukemia inhibitory factor
US20040030097A1 (en) Peptide mimetics
PT1105485E (pt) Dna e polipeptídeos de il-1 epsilon humana
US7241868B1 (en) Crystallization of Glucocorticoid Receptor
EP1690871B1 (en) Xrec2 DNAs and polypeptides
JP2002112782A (ja) 抗血栓活性を有する蛋白質及びその製造法
JP2001526893A (ja) Ｔｉｇｉｒｒｄｎａおよびポリペプチド
AU4050593A (en) Receptor-type tyrosine kinase-like molecules

Legal Events

Date Code Title Description
A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20040216

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20040405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040525

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20050517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050727

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20050811

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20050908

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20071105

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20071108

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20071203